Over the past two decades there has been a great deal of interest in the development of
inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from …

Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S-and M-phases
of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is …

Cyclin-dependent kinases (CDKs) are proteins pivotal to a wide range of cellular functions,
most importantly cell division and transcription, and their dysregulations have been …

Enhanced and deregulated expression of N-MYC, a member of the MYC family of
transcription factors, drives the development of multiple tumors, including tumors of the …

Blockade of the checkpoint inhibitor programmed death 1 (PD1) has demonstrated
remarkable success in the clinic for the treatment of cancer; however, a majority of tumors …

Simple Summary This review provides an overview of the state of knowledge and general
understanding of CDK inhibitors currently under development or clinically approved, with a …

This paper is in recognition of the 100th birthday of Dr. Herbert Tabor, a true pioneer in the
polyamine field for over 70 years, who served as the editor-in-chief of the Journal of …

Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an
attractive therapeutic target for many cancers, especially for cancers driven by transcriptional …

Neuroblastoma is the most common extracranial solid tumor in infants, arising from
developmentally stalled neural crest-derived cells. Driving tumor differentiation is a …

Pulmonary arterial hypertension (PAH) is a devastating disease with poor prognosis and
limited therapeutic options. We screened for pathways that may be responsible for the …